Men and women investors, regardless of their personal preferences, cannot help taking a serious note of this stock. Sexual dysfunctions are common. OTC stock from distant Australia in this profitable growth area is a valuable stock investment opportunity.
The prostate treatment business of this company grew annually by more than 65% over the six months ended December 2007. This comes with a nearly 20% growth in overall sales. This shows that the company has been successful in moving horizontally away from its core revenue lines in sexual problems of men.
The company has a network of about 20 clinics throughout Australia and New Zealand. This insulates the company partly from shifting loyalties of physicians. Investors can look forward to the stock developing its own strength from satisfied customers. The company has over 50 qualified medical personnel on its rolls.
Company expansions in Japan and China make this stock even more attractive for global investors. The company will be able to leverage its patents and know-how very well in these large and lucrative markets. It has closed 2007 with assets of over $47 million against equity of about $30 million. Net income before tax has jumped annually by over 150% during the most recent quarter. The management has taken effective steps to ensure that foreign operations do not drain cash. It has also started consulting for a chain of clinics in Indonesia.
The company is optimistic about 2008 prospects. The management has paid back bank loans ahead of due dates during 2007. Overall, this stock meets all business conditions for rapid and profitable growth.
Let us hear your thoughts below: